Fotis Sakellaridis, M.B.A. – President / CEO
Fotis Sakellaridis is a Chemist and holds an MBA from the MCE in Brussels and the IMD of Lausanne in the areas of Marketing and Management.
Fotis is a founding partner and Managing Director of Proton Pharma SA from 2007 till today. He started his career in 1988 as a medical rep of Glaxo S.A. From 1990 till 1997 he was employed by Astra Hellas S.A. where he held the positions of Product Manager, Marketing Manager and Marketing and Sales Director. From 1997 till 2007 he served as Managing Director of Janssen-Cilag Greece S.A. In parallel during the period 2002-2004 he served as Vice President Market Development Ortho Biotech Europe, M.East and Africa.
Fotis held various positions in many Industry associations, amongst others, Vice President of the Hellenic Association of Pharmaceutical Industry, President of the Pharmaceutical Committee of the American-Hellenic Chamber of Commerce, Vice President of the Greek PhRMA, member of the Greek Network of the Corporate Social Responsibility, member of the Association of Chief Executive Officers and President of the Greek Pharmaceutical Marketing Association.
Christos Kiamouris, M.D., Ph.D. – Medical Director
Christos Kiamouris completed his studies at the Medical School of Athens and at the National School of Public Health. He specialized in Internal Medicine, in Hematology and in Oncology. At the same time he was trained in Methodology of Clinical Research, in Epidemiology and Statistics and on the Environmental and Occupational Medicine. Christos completed successfully a graduate program at Harvard University about Negotiating Skills and Telephone Medicine Methodology. He worked for the Oncological Department of «St. Anargyri ” and Alexandra University Hospital Department.
Christos has participated as a speaker at several international conferences and has worked with international centers in preparing Clinical Studies, focusing in neoplastic diseases. He has published his academic activities in many international magazines in the fields of Oncology – Hematology and Epidemiology. Since 2002 he works in the field of pharmaceutical companies as Medical Director both in Greece and abroad and Director of Clinical Research (companies Novartis , Janssen Cilag, Proton Pharma). Since 2013 he is the Medical Director of Theracell.
Christina Ligoudistianou, Ph.D. – Scientific Director
Christina Ligoudistianou studied Biology at the Aristotle University of Thessaloniki. She holds a Ph.D in Immunology & Molecular biology from “Alexander Fleming” Biomedical Sciences Research Center. In 2003 she carried out part of her research work in the Laboratory of Molecular Enzymology at the Institute for Structural Biology “Jean-Pierre Ebel”, in Grenoble France, during an annual Marie Curie” scholarship.
In 2004 she studied the effect of chemical compounds on human cancer cell lines, in a biotechnology company. In 2005, she worked in the laboratory of Dr. George Panayotou, Researcher of Molecular Oncology at the “Alexander Fleming” Biomedical Sciences Research Center. While studying the effects of chemicals compounds in human glioma and bladder cancer cells, she was also performing HPLC analysis in patients’ blood, for the pharmaceutical company WYETH.
From 2006 till 2013, she’ s been working in ProCell SA, as a head of the laboratory for the isolation and preservation of umbilical cord blood and dental stem cells.
Maria Kontou, M.Sc. – Laboratory Director
Maria Kontou holds a Biochemistry degree from the University of Ioannina, Greece. She started her carrier at the National Center for Scientific Research (NCSR) “Democritos” as a collaborating scientist participating in a research program regarding growth and apoptosis in human glomerular epithelial cells. She continued her education at the Medical School of Athens for a master degree on “Clinical and Laboratory Medicine” and elaborated her project at the Genetic Research Center “Choremeio” at the Children’s Hospital “Agia Sophia” under the supervision of professor Dr. E. Kanavakis. Her thesis was involved with new technics for detecting carriers with Spinal Muscular Atrophy (SMA).
After her graduation she worked from 2006 to 2013 in a private genetic center where she became an expert in cytogenetic analyses and cell cultures but also had the chance to be trained in all the departments of the center such as the Biochemistry and the Molecular Genetic department. From 2015 she’s been working in Theracell as a Laboratory Director.
Sofia Galatoula – CFO